Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Open accessThe DOI matches its Crossref record; 80 of the 82 references it cites were found in a registry or an index.
Abstract
Checkpoint blockade immunotherapy targeting the PD-1/PD-L1 inhibitory axis has produced remarkable results in the treatment of several types of cancer. Whereas cytotoxic T cells are known to provide important antitumor effects during checkpoint blockade, certain cancers with low MHC expression are responsive to therapy, suggesting that other immune cell types may also play a role. Here, we employed several mouse models of cancer to investigate the effect of PD-1/PD-L1 blockade on NK cells, a population of cytotoxic innate lymphocytes that also mediate antitumor immunity. We discovered that PD-1 and PD-L1 blockade elicited a strong NK cell response that was indispensable for the full therapeutic effect of immunotherapy. PD-1 was expressed on NK cells within transplantable, spontaneous, and genetically induced mouse tumor models, and PD-L1 expression in cancer cells resulted in reduced NK cell responses and generation of more aggressive tumors in vivo. PD-1 expression was more abundant on NK cells with an activated and more responsive phenotype and did not mark NK cells with an exhausted phenotype. These results demonstrate the importance of the PD-1/PD-L1 axis in inhibiting NK cell responses in vivo and reveal that NK cells, in addition to T cells, mediate the effect of PD-1/PD-L1 blockade immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PD-1 (a.k.a. CD279) is expressed on activated T cells as well as other cells including but not limited to B cells, natural killer (NK) cells, and myeloid cells (Hsu et al., 2018; Nam et al., 2019).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Hsu et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W.-K., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Cited by
Items 701–800 of 848
Leng, G., Gong, H., Liu, G., Kong, Y., Guo, L., & Zhang, Y. (2024) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2024.130592 · Cited by 1
Personalized Medicine in Clinical Management of Breast Cancer: Where Do We Stand?
Kumar, A., Parama, D., Rana, V., Daimary, U. D., Girisa, S., & Kunnumakkara, A. B. (2024) · Springer eBooks · doi:10.1007/978-981-99-3746-2_28 · Cited by 3
Phenotypic Heterogeneity of Dysfunctional Natural Killer Cells During Chronic Infection or Cancer
Pouxvielh, K., Marotel, M., Rousseaux, N., Picq, L., Benezech, S., Nombel, A., Kern, N., Marçais, A., & Walzer, T. (2025) · Springer eBooks · doi:10.1007/978-3-662-68816-8_30-1 · Cited by 1
Palamà, M. E. F., Gay-Para, T. F., Borka, G., Boucherit, N., Gorvel, L., & Scaglione, S. (2025) · Springer eBooks · doi:10.1007/978-3-662-68816-8_51-1 · Cited by 1
Feodoroff, M., Mogollón, I., Hamdan, F., Luck, T. J., Kumari, R., Bottega, P., Sandberg, J., Romppanen, E., Paavolainen, L., Malmstedt, M., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1760889 · Cited by 1
Strategies and Techniques for NK Cell Phenotyping
Ziqing, C., Lundqvist, A., & Witt, K. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9650-6_6
Cappello, S. (2020) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8083
エレーヌ・シクスー『内部』にあらわれる二元性について(研究発表要旨)
上田, 章. (2008) · フランス語フランス文学研究 · doi:10.20634/ellf.93.0_207
Mechanisms of Clearance of MHC I-deficient Tumors Induced by STING Agonists
Nicolai, C. J. (2020) · eScholarship (California Digital Library)
Self-citationROLE OF PD-1/PD-L1 AXIS IN REGULATING FUNCTIONS OF INNATE IMMUNE CELLS IN THE TREATMENT OF CANCER
Storti, C. (2019) · Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) · doi:10.13130/storti-chiara_phd2019-01-29
Mechanisms of Resistance to Immunotherapy in Cutaneous Melanoma
Anichini, A., & Mortarini, R. (2021) · Springer eBooks · doi:10.1007/978-3-030-64009-5_19
Induced pluripotent stem cells in intestinal diseases
Fakoya, A., Omole, A. E., Satyadev, N., & Okaruefe, C. O. (2021) · INTESTINE · doi:10.1016/b978-0-12-821269-1.00003-5
IMMUNOSUPPRESSIVE MECHANISMS IN THE TUMOR MICROENVIRONMENT MEDIATING RESISTANCE TO IMMUNOTHERAPY
Vick, S. C. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/kp4y-f910
Challenges for NK cell-based therapies: What can we learn from lymph nodes?
Rethacker, L., Dulphy, N., & Caignard, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824375-6.00002-3
Cortés-Kaplan, S. (2021) · uO Research (University of Ottawa) · doi:10.20381/ruor-26767
Enhancing Anti-Cancer Properties of Human Natural Killer Cells
Fitzgerald, A. A. (2021) · DigitalGeorgetown (Georgetown University Library)
Large granular lymphocytosis: A novel association with immunotherapy
Nedumannil, R., & Juneja, S. (2021) · Hematological Oncology · doi:10.1002/hon.2942
“Although PD‐1/PD‐L1 inhibitors have been shown to result in NK‐cells with increased functional activity, these agents have not been specifically associated with NK‐cell lymphocytosis.(6) Mechanistically, the NK‐cell expansion seen in this case can be better attributed to IL‐15/IL‐15Rα‐Fc, and appears to clinically man…”
BackgroundPascheto, I. (2020) · Lu Zone Ul (Laurentian University)
9052 京都梅津長福寺境内の構成 (1) : 『大梅山長福禅寺全盛古大図』と塔頭の成立時期
伊藤, 毅. (1990) · 学術講演梗概集. F, 都市計画, 建築経済・住宅問題, 建築歴史・意匠
Brisbane River Expressways as Landscape Urbanism
Thomas, G. S. (2001)
Jia, J., Heng, G., Wang, M., Wang, L., Li, Y., Zhang, Y., Zhang, C., Yang, Z., Ruan, Z., & Qian, C. (2021) · Research Square · doi:10.21203/rs.3.rs-1115691/v1
Maprotiline Prompt the Anti-tumor Effect by Inhibiting the PD-L1 in Mice Burdened MelanomaPreprint
Zhao, T., Li, Y., Liu, M., Zhou, L., Wu, Z., Chen, H., Guo, J., Gao, M., Zhong, J., Wang, M., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1172486/v1
Immunotherapies and their moderation
Anisman, H., & Kusnecov, A. W. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91904-3.00006-9
Strecker, M. (2022) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.68021
Wen, S., Zeng, H., An, K., Wu, S., Huang, X., Shao, Z., Bai, J., & Yin, T. (2022) · Research Square · doi:10.21203/rs.3.rs-2296058/v1
魏, 超. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.133714
Data from ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity
Haines, B. B., Denslow, A., Grzesik, P., Lee, J. S., Farkaly, T., Hewett, J., Wambua, D., Kong, L., Behera, P., Jacques, J., et al. (2023) · doi:10.1158/2326-6066.c.6550257
Haines, B. B., Denslow, A., Grzesik, P., Lee, J. S., Farkaly, T., Hewett, J., Wambua, D., Kong, L., Behera, P., Jacques, J., et al. (2023) · doi:10.1158/2326-6066.22543431
Tang, Y., Xu, Q., Hu, L., Yan, X., Feng, X., Yokota, A., Wang, W., Zhan, D., Krishnamurthy, D., Ochayon, D. E., et al. (2023) · doi:10.1158/2159-8290.c.6549403
Felices, M., Wesley, E., Bendzick, L. E., Kodal, B., Hopps, R., Grzywacz, B. J., Hinderlie, P., Miller, J. S., & Geller, M. A. (2023) · doi:10.1158/2326-6066.c.6551230
Systemic Oncosphere: Host Innate Immune System
Saw, P. E., & Song, E. (2023) · Springer eBooks · doi:10.1007/978-981-99-1183-7_19
Unleashing the Potential of Natural Killer Cells in Immunotherapy for Glioblastoma and Brain Tumors
Farhangnia, P., Khorramdelazad, H., Ghiaee, P., Fard, S. R., & Delbandi, A. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2023_186
Les cellules lymphocytaires innées dans l’immunosurveillance des tumeurs métastatiques
Rethacker, L. (2021) · theses.fr (ABES) · doi:10.70675/f6fd9463z4034z4eeaza8fazdddec7bd4cb6
Zhang, Z., Liu, Y., Huang, X., Li, Y., Zhang, X., Pan, Q., Cai, L., Lu, J., Zhang, Y., Gao, J., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4087919/v1
Sulfarotene Inhibits Colorectal Cancer via Mitigating Natural-Killer-Cell-Induced Stemness
Hu, K., Dong, Y., Zhang, J., Liu, M., Sun, X., Cao, X., Zhang, P., & Liu, T. (2024) · Pharmaceuticals · doi:10.3390/ph17030387
“While the role of T cells and tumor-associated macrophages (TAMs) has been extensively discussed in the context of ICB treatments [8,9], emerging evidence highlights the crucial involvement of innate immune cells, particularly natural killer (NK) cells, in this process [10].”
BackgroundChallenges and Recent Advances in NK-Mediated Adoptive Cell Therapies against Cancer
Zhang, T. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004181
Zulfiqqar, A., Soerohardjo, I., Hendri, A. Z., & Heriyanto, D. S. (2023) · Journal of Experimental and Clinical Medicine
Advancements in the Therapeutic Application of Natural Killer Cells in Acute Myeloid Leukemia
曲, 逸. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.14102659
The Diverse Roles of the Tumour Microenvironment in Carcinogenesis
Al-Janabi, I. I. (2024) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v7i2.1464 · Cited by 1
“The interaction of PD-1 expressed in NK cells with PD-L1 expressed in cancer cells can decrease the responses of NK cells, and blocking these proteins can increase NK immune responses and cytotoxicity in mouse tumor models [66,67].”
BackgroundVirazels, M. (2023) · theses.fr (ABES) · doi:10.70675/1ffc7bb5z666fz49d3zb5b9z81ce3e4d33d5
The Role of Congenital Cytotoxic Lymphocytes in PD-1/PD-L1 Inhibitor Treatment of Lung Cancer
袁, 坤. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.14123179
Isocitrate Dehydrogenase Defects In Gliomas: PATH For Potential Therapeutics Hasit Shah
Shah, H. (2024) · International journal of high school research · doi:10.36838/v6i7.8
Wang, K., Wang, X., Meng, X., Zhang, G., & Cai, G. (2025) · Annals of Nuclear Medicine · doi:10.1007/s12149-025-02057-0
“In addition to its effects on T cells, previous studies have shown that activated NK cells can also express PD-1, and their antitumor functions may be impaired by PD-L1 expressed on tumor cells [26–28].”
Feng, Y., Hu, Y., Liu, J., Zhang, X., Zhang, Y., Wang, Z., & Pu, K. (2025) · Angewandte Chemie · doi:10.1002/ange.202507765
Evaluating an immunotherapeutic approach to photodynamic therapy for glioblastoma
Kim, Y. S., Kang, B. G., Yang, S.-H., Jeun, S., & Park, S. A. (2025) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2025.105244
Immunotherapy for Pediatric Cancer
Rashed, W. M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00769-8_246
Huang, J.-P., Tsai, C., Hsieh, P.-Y., & Chen, S. (2025) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000583
“7 In different cancer lines, functional impairment of NK cells in B-CLL was also observed with decreased activating receptors and cytokines secretion when PD-1 was presented, which could be partially reversed by anti-PD-1/PD-L blockade.”
Li, R., Zhao, A., Yan, C., Li, B., & Hao, Z. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003940
PD-1 Expression Promotes Immune Evasion in B-ALL
Casado-García, A., García-Aguilera, G., Pozo, J., Oak, N., Bárrena, S., Ruiz-Corzo, B., Lalchandani, J., Chamorro-Vera, A., Castillo‐Robleda, A., Soriano, B., et al. (2025) · Hematology Reports · doi:10.3390/hematolrep17060061
“These findings suggest that PD-1 targeting released the immune-suppressive regulation and restored the tumor-specific cytotoxicity of either cytotoxic T lymphocytes or NK cells, which are the cellular components mediating the effects of the PD-1 blockade [55,56].”
Optimizing Natural Killer Cellular Therapy in Acute Myeloid Leukemia
George, B., Pandey, M. R., Herstein, J. E., & Maiti, A. (2025) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001262
Seo, M.-J., Jeong, J. H., Park, H. N., Baek, I.-P., Park, J. W., Kim, S. Y., Choi, Y. R., Choi, S., Ham, S. M., Park, D., et al. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.201120
“49,50 Our preclinical findings are in line with a phase I 4 and phase 2 5 clinical trials that demonstrate the efficacy of CLDN18.”
Tsuneyoshi, N., Hosoya, T., Takeno, Y., Saitoh, K., Murai, H., Amimoto, N., Tatsumi, R., Watanabe, S., Hasegawa, Y., Kikkawa, E. F., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26741663
Chapelain, O. L., Jadoui, S., Gros, A., Barbaria, S., Benmeziane, K., Ollivier, V., Dupont, S., Nomenjanahary, M. S., Mavouna, S., Rogozarski, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26694465
Chapelain, O. L., Jadoui, S., Gros, A., Barbaria, S., Benmeziane, K., Ollivier, V., Dupont, S., Nomenjanahary, M. S., Mavouna, S., Rogozarski, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26694480
Liu, Y., Xu, Q., Deng, F., Zheng, Z., Luo, J., Wang, P., Zhou, J., Lu, X., Zhang, L., Chen, Z., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22613720
Self-citationChapelain, O. L., Jadoui, S., Gros, A., Barbaria, S., Benmeziane, K., Ollivier, V., Dupont, S., Nomenjanahary, M. S., Mavouna, S., Rogozarski, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26694483
Chapelain, O. L., Jadoui, S., Gros, A., Barbaria, S., Benmeziane, K., Ollivier, V., Dupont, S., Nomenjanahary, M. S., Mavouna, S., Rogozarski, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25424738
Qu, J., Wu, B., Chen, L., Wen, Z., 方梁杰, Zheng, J., Shen, Q., Heng, J., Zhou, J., & Zhou, J. (2024) · Figshare · doi:10.6084/m9.figshare.25744392
Maya, J. (2023) · eCommons (Cornell University) · doi:10.7298/6r2r-3p30 · Cited by 1
CATCH ME IF YOU CAN: DETECTING IMMUNE-CANCER CELL INTERACTIONS FOR BETTER IMMUNOTHERAPY
Quebbemann, K. M. (2023) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/pkhs-gd31
Chapelain, O. L., Jadoui, S., Gros, A., Barbaria, S., Benmeziane, K., Ollivier, V., Dupont, S., Nomenjanahary, M. S., Mavouna, S., Rogozarski, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26694477
Chapelain, O. L., Jadoui, S., Gros, A., Barbaria, S., Benmeziane, K., Ollivier, V., Dupont, S., Nomenjanahary, M. S., Mavouna, S., Rogozarski, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25424796
Additional file 1 of Downregulation of NKG2DLs by TGF-β in human lung cancer cells
Lee, Y. S., Choi, H., Cho, H.-R., Son, W.-C., Park, Y.-S., Kang, C.-D., & Bae, J. (2021) · Figshare · doi:10.6084/m9.figshare.14966366
Chapelain, O. L., Jadoui, S., Gros, A., Barbaria, S., Benmeziane, K., Ollivier, V., Dupont, S., Nomenjanahary, M. S., Mavouna, S., Rogozarski, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26694489
Chapelain, O. L., Jadoui, S., Gros, A., Barbaria, S., Benmeziane, K., Ollivier, V., Dupont, S., Nomenjanahary, M. S., Mavouna, S., Rogozarski, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26694471
Yu, D., Yang, P., Lu, X., Huang, S., Liu, L., & Fan, X. (2023) · Figshare · doi:10.6084/m9.figshare.23658108
Wang, X., Liu, X., Dai, H., & Junmei, J. (2024) · Figshare · doi:10.6084/m9.figshare.26694144
Immune-endothelial axis in liver homeostasis and inflammation
See, J.-X. (2022) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00032073
Girardin, M. (2023) · Infoscience (Ecole Polytechnique Fédérale de Lausanne) · doi:10.5075/epfl-thesis-8912
Yu, D., Yang, P., Lu, X., Huang, S., Liu, L., & Fan, X. (2023) · Figshare · doi:10.6084/m9.figshare.23658102
Wang, X., Liu, X., Dai, H., & Junmei, J. (2024) · Figshare · doi:10.6084/m9.figshare.25422386
Chapelain, O. L., Jadoui, S., Gros, A., Barbaria, S., Benmeziane, K., Ollivier, V., Dupont, S., Nomenjanahary, M. S., Mavouna, S., Rogozarski, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26694474
Wang, X., Liu, X., Dai, H., & Junmei, J. (2024) · Figshare · doi:10.6084/m9.figshare.25422432
Chapelain, O. L., Jadoui, S., Gros, A., Barbaria, S., Benmeziane, K., Ollivier, V., Dupont, S., Nomenjanahary, M. S., Mavouna, S., Rogozarski, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26694486
Chapelain, O. L., Jadoui, S., Gros, A., Barbaria, S., Benmeziane, K., Ollivier, V., Dupont, S., Nomenjanahary, M. S., Mavouna, S., Rogozarski, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26694468
Martinkova, L., Zatloukalová, P., Kucerikova, M., Friedlová, N., Tylichová, Z., Zavadil-Kokas, F., Hupp, T. R., Coates, P. J., & Vojtesek, B. (2024) · Figshare · doi:10.6084/m9.figshare.26952316
Davis-Marcisak, E. F., Fitzgerald, A. A., Kessler, M. D., Danilova, L., Jaffee, E. M., Zaidi, N., Weiner, L. M., & Fertig, E. J. (2021) · Figshare · doi:10.6084/m9.figshare.15145874
Natural Killer cell immune engagers to induce optimal anti-tumor activity.
Chiu, E. (2021) · University of Minnesota Digital Conservancy (University of Minnesota)
Zanth, H., Multhoff, G., & München, T. U. (2024)
Role of FcγRs in anti-OX40 based immunotherapies
Costoya, C. (2023) · UCL Discovery (University College London)
Defining the critical characteristics of Natural Killer cell memory
Arellano-Ballestero, H. (2024) · UCL Discovery (University College London)
Verma, D., Bansal, A., Sharma, R., & Mehta, S. (2025) · Specialty journal of Pharmacognosy Phytochemistry and Biotechnology · doi:10.51847/upwt4sy90e
Chevrier, S., Richard, C., Adotévi, O., Ayyoub, M., Chaput, N., Damotte, D., Ghiringhelli, F., Hacein‐Bey‐Abina, S., Tartour, É., Zitvogel, L., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2306
Shaban, D., Plackoska, V., Liang, Y., Najm, N., Robert, F., Huang, S., & Nijnik, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.19.700060
Rasal1 impairment unleashes anticancer immunity - a focus on T cellsPreprint
Issa, M. E., & Schcolnik‐Cabrera, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.19.700452
PD-L1 is an intrinsic switch for natural killer cell-mediated, TRAIL-dependent antiviral function
Frank, K., Sharma, H., Motakis, E., Nourbakhsh, N., Abeynaike, S. A., Huynh, T. R., Jones, C. A., Johnson, S. K., Tompkins, S. M., & Paust, S. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.116939
“Though PD-1 can regulate NK cell function, 33 we did not observe robust PD-1 expression on IAV-primed NK cells in C57Bl/6 or Rag1-KO mice but found robust upregulation of PD-L1.”
Tissue-Specific Spatial Regulation of Innate Immune Checkpoints in Cancer
Stojanovic, A., Giorgetta, S., Vonhören, D., Krieghoff‐Henning, E., Platten, M., Loges, S., Tugues, S., & Cerwenka, A. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-2112
Serrato, Ibarra, F. S., Mariscal‐Ramírez, I., Torres-Bustamante, M. I., Totsuka-Sutto, S. E., Vázquez-Urrutia, J. R., Alcaraz-Wong, A. A., Contreras-Haro, B., & Ortiz‐Lazareno, P. C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041634
“…that while NKG2D and DNAM-1 are essential for recognizing stress-induced ligands—such as MICA/B and CD155—on malignant cells [22], the tumor microenvironment (TME) often drives a functional “imbalance” by upregulating TIGIT and PD-1, which leads to NK cell exhaustion and immune evasion [19,23].”
Volkov, A. S., & Kuzmin, D. I. (2023) · Archive of International Journal of Cancer and Allied Science · doi:10.51847/hmshy9e0oq
Yamaguchi, A., Suzuki, H., Takasuga, S., Tatematsu, M., Fuchimukai, A., Endo, T., Kaya, H., Morishita, A., Seki, S., Imai, K., et al. (2026) · OncoImmunology · doi:10.1080/2162402x.2026.2639723
“43,44 However, other reports suggest that PD-1 is not a major checkpoint molecule for NK cells in tumors due to its limited expression.”
Network analysis predicts pembrolizumab response in advanced NSCLC with PD-L1 < 50%
Occhipinti, M. A., Cruoglio, A., Marchesi, S., Prelaj, A., Petrilli, M., Rughetti, A., Ambrosini, P., Ferretti, E., Proto, C., Ganzinelli, M., et al. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04268-5
“Multiple pieces of evidence from both clinical and preclinical investigations underscore the pivotal role of innate immune cells in the realm of PD-1 targeted therapy [27, 28].”
Rôle des cellules dendritiques conventionnelles de type 1 dans l'immunosurveillance des cancers
Mattiuz, R. (2019) · theses.fr (ABES) · doi:10.70675/2685bed4zde26z40eezad12zdac1c487379e
Défauts fonctionnels des cellules NK en contexte de stimulation chronique
Marotel, M. (2019) · theses.fr (ABES) · doi:10.70675/1dcb97a5za482z4664zaaf6z62a53817eea9 · Cited by 1
Metadata
- Authors
- Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., Zhang, L., Iannello, A., Mathur, N., Jardine, K. E., Kirn, G. A., Bell, J. C., McBurney, M. W., Raulet, D. H., & Ardolino, M.
- Affiliations
- University of California, Berkeley (US)
- University of Ottawa (CA)
- Corresponding author
- Raulet, David H.
- Ardolino, Michele
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2018-09-10
- Volume
- 128
- Issue
- 10
- Pages
- 4654-4668
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6159991
- OpenAlex
- W2890056446
- Cited by
- 817
- References
- 82
- Citations by year
- 2026: 57 · 2025: 96 · 2024: 107 · 2023: 101 · 2022: 106 · 2021: 148 · 2020: 124 · 2019: 68 · 2018: 7
- FWCI
- 37.29
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- National Cancer Institute (R01CA093678)
- National Institute of General Medical Sciences (T32GM007232)
- National Institute of Allergy and Infectious Diseases (R01AI113041)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- natural killer cells, PD-1, PD-L1, immune checkpoint blockade, cancer immunotherapy, NK cell exhaustion, antitumor immunity, NK cell activation, tumor immunosuppression, MHC expression
- MeSH terms
- Animals, Humans, Immunotherapy, Killer Cells, Natural, Neoplasms, Experimental, Mice, Knockout, K562 Cells, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.